NCT04763902

Brief Summary

The long-term goal of this study is to determine the efficacy of time restricted eating (TRE) for improving metabolic health and preventing endometrial cancer. The primary objective of the protocol is to conduct a 14-week two-arm randomized crossover trial of a dietary intervention to evaluate the feasibility, fidelity and preliminary acceptability of a TRE intervention among Native Hawaiian/Pacific Islander women at risk for developing endometrial cancer, and to provide proof of principle that TRE can improve metabolic health in this population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 8, 2021

Completed
10 days until next milestone

Study Start

First participant enrolled

February 18, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 21, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 10, 2022

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

November 30, 2023

Status Verified

November 1, 2023

Enrollment Period

1.3 years

First QC Date

February 8, 2021

Last Update Submit

November 28, 2023

Conditions

Outcome Measures

Primary Outcomes (6)

  • Proportion of Women Referred that are Consented

    Feasibility of the TRE intervention will be measured by calculating a proportion (%) of women who were referred that were consented into the study. The study will be considered feasible if \> 70% of participants are consented and retained.

    From baseline to Visit 5 (Week 14)

  • Attrition as a Function of Time

    Number of participants who withdraw throughout the course of the study.

    From baseline to Visit 5 (Week 14)

  • Percent of Scheduled Assessments Completed

    Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.

    From baseline to Visit 5 (Week 14)

  • Number of TRE-Adherent Days per Week

    Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-18 hours per day during the TRE phase according to a mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.

    From baseline to Visit 5 (Week 14)

  • Percentage of Meals Delivered On Schedule

    Feasibility of the TRE intervention will be measured by calculating a percentage of meals delivered on schedule.

    From baseline to Visit 5 (Week 14)

  • Fidelity of Time Restricted Eating (TRE) Intervention

    Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%.

    From baseline to Visit 5 (Week 14)

Secondary Outcomes (9)

  • Change in blood pressure assessed via electronic blood pressure monitor

    Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)

  • Change in waist circumference assessed via measuring tape

    Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)

  • Change in BMI assessed via height and weight

    Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)

  • Change in fasting blood glucose assessed via blood draw

    Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)

  • Change in HOMA-IR assessed via blood draw

    Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)

  • +4 more secondary outcomes

Study Arms (2)

Time Restricted Eating (TRE) Schedule

EXPERIMENTAL

For 8 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calories-containing beverages within an 8 to 10-hour period that fits their schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day).

Behavioral: Time Restricted Eating (TRE) Schedule

Control Schedule

NO INTERVENTION

For 4 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals, and a standardized breakfast and snacks menu. All meals and snacks will be culturally competent, and meal plans will be individualized to meet weight maintenance energy requirements.

Interventions

\[See arm/group descriptions\]

Time Restricted Eating (TRE) Schedule

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All Aims:
  • Native Hawaiian/Pacific Islander females aged 18 years or older
  • Overweight or obese (BMI\>25kg/m2) OR have a history of non-insulin dependent diabetes OR have a history of complex atypical endometrial hyperplasia
  • Have a working cell phone that can download an App
  • Able to use cell phone during day (e.g. at work)
  • Not a night shift worker
  • Applicable Only to Aims 2 \& 3:
  • Able to attend study visits at the Huntsman Cancer Institute Center for HOPE

You may not qualify if:

  • All Aims:
  • Unable to provide informed consent
  • Applicable Only to Aims 2 \& 3:
  • Necessity of a special diet that precludes adjustment of meal timing and/or macronutrient content
  • Have a history of insulin dependent diabetes
  • Have a history of hysterectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

Location

MeSH Terms

Conditions

Endometrial Neoplasms

Interventions

TrehalaseAppointments and Schedules

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

DisaccharidasesGlycoside HydrolasesHydrolasesEnzymesEnzymes and CoenzymesOrganization and AdministrationHealth Services Administration

Study Officials

  • Mary Playdon, PhD, MPH

    University of Utah

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Investigator

Study Record Dates

First Submitted

February 8, 2021

First Posted

February 21, 2021

Study Start

February 18, 2021

Primary Completion

June 10, 2022

Study Completion

September 30, 2022

Last Updated

November 30, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations